Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature

References

• Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–567. doi: 10.1002/ajh.25791
   PubMed Web of Science ®Google Scholar
• Fonseca R, Debes-Marun CS, Picken EB, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102(7):2562–2567. doi: 10.1182/blood-2003-02-0493
   PubMed Web of Science ®Google Scholar
• Bisht K, Walker B, Kumar SK, et al. Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. Expert Rev Hematol. 2021;14(12):1099–1114. doi: 10.1080/17474086.2021.1983427
   PubMed Web of Science ®Google Scholar
• Manier S, Salem KZ, Park J, et al. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100–113. doi: 10.1038/nrclinonc.2016.122
   PubMed Web of Science ®Google Scholar
• Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17(9):543–556. doi: 10.1038/nrc.2017.63
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International myeloma Working Group. Blood. 2016;127(24):2955–2962. doi: 10.1182/blood-2016-01-631200
   PubMed Web of Science ®Google Scholar
• Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021;11(4):1–11. doi: 10.1038/s41408-021-00474-8
   PubMed Web of Science ®Google Scholar
• Hanamura I. Gain/Amplification of chromosome arm 1q21 in multiple myeloma. Cancers (Basel). 2021;13(2):256. doi: 10.3390/cancers13020256
   PubMed Web of Science ®Google Scholar
• Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(34):4325–4332. doi: 10.1200/JCO.2012.48.4923
   PubMed Web of Science ®Google Scholar
• Ross FM, Avet-Loiseau H, Ameye G, et al. Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97(8):1272–1277. doi: 10.3324/haematol.2011.056176
   PubMed Web of Science ®Google Scholar
• Burroughs Garcìa J, Eufemiese RA, Storti P, et al. Role of 1q21 in multiple myeloma: from pathogenesis to possible therapeutic targets. Cells. 2021;10(6):1360. doi: 10.3390/cells10061360
   PubMed Web of Science ®Google Scholar
• Zhou P, Li W, Zuo S, et al. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities. Leuk Lymphoma. 2023;64:1373–1388. doi: 10.1080/10428194.2023.2216325
   PubMed Web of Science ®Google Scholar
• Sawyer JR, Tricot G, Mattox S, et al. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood. 1998;91(5):1732–1741. doi: 10.1182/blood.V91.5.1732
   PubMed Web of Science ®Google Scholar
• Sawyer JR, Tian E, Thomas E, et al. Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12∼23 amplicon. Br J Haematol. 2009;147(4):484–494. doi: 10.1111/j.1365-2141.2009.07869.x
   PubMed Web of Science ®Google Scholar
• Sawyer JR, Tian E, Heuck CJ, et al. Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood. 2014;123(16):2504–2512. doi: 10.1182/blood-2013-12-546077
   PubMed Web of Science ®Google Scholar
• Fabris S, Ronchetti D, Agnelli L, et al. Transcriptional features of multiple myeloma patients with chromosome 1q gain. Leukemia. 2007;21(5):1113–1116. doi: 10.1038/sj.leu.2404616
   PubMed Web of Science ®Google Scholar
• Trasanidis N, Katsarou A, Ponnusamy K, et al. Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma. Blood. 2022;139(13):1939–1953. doi: 10.1182/blood.2021014391
   PubMed Web of Science ®Google Scholar
• Boyle EM, Blaney P, Stoeckle J, et al. Structural heterogeneity of chromosome 1q drives outcome in newly diagnoses myeloma. Blood. 2022;140(Supplement 1):4253–4254. doi: 10.1182/blood-2022-165467
   Google Scholar
• Slomp A, Moesbergen LM, Gong J-N, et al. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Blood Adv. 2019;3(24):4202–4214. doi: 10.1182/bloodadvances.2019000702
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869. doi: 10.1200/JCO.2015.61.2267
   PubMed Web of Science ®Google Scholar
• Greipp PR, Miguel JS, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420. doi: 10.1200/JCO.2005.04.242
   PubMed Web of Science ®Google Scholar
• Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210–2221. doi: 10.1038/leu.2009.174
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Barlogie B, Smith TL, et al. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med. 1991;115(12):931–935. doi: 10.7326/0003-4819-115-12-931
   PubMed Web of Science ®Google Scholar
• Zamagni E, Barbato S, Cavo M. How I treat high-risk multiple myeloma. Blood. 2022;139(19):2889–2903. doi: 10.1182/blood.2020008733
   PubMed Web of Science ®Google Scholar
• Perrot A, Lauwers-Cances V, Tournay E, et al. Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol. 2019;37(19):1657–1665. doi: 10.1200/JCO.18.00776
   PubMed Web of Science ®Google Scholar
• Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159–170. doi: 10.1038/s41375-018-0196-8
   PubMed Web of Science ®Google Scholar
• Abdallah NH, Binder M, Rajkumar SV, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12(1):1–9. doi: 10.1038/s41408-022-00611-x
   PubMed Web of Science ®Google Scholar
• D’Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) Report within the HARMONY Project. J Clin Oncol. 2022;40(29):3406–3418. doi: 10.1200/JCO.21.02614.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2021;32(3):309–322. doi: 10.1016/j.annonc.2020.11.014
   PubMed Web of Science ®Google Scholar
• Kumar SK, Callander NS, Adekola K, et al. Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(12):1281–1301. doi: 10.6004/jnccn.2023.0061
   PubMedGoogle Scholar
• Bisht K, Fukao T, Chiron M, et al. Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma. Cancer Med. 2023;12(20):20332–20352. doi: 10.1002/cam4.6619
   PubMed Web of Science ®Google Scholar
• Janssen. DARZALEX Prescribing Information. 2023. cited 2024 Mar 4.
   Google Scholar
• Sanofi Co. Ltd. Sarclisa® (isatuximab) [package insert]. 2023. cited 2024 Mar 4.
   Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–1560. doi: 10.1016/S0140-6736(15)01120-4
   PubMed Web of Science ®Google Scholar
• Sive J, Cuthill K, Hunter H, et al. Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK myeloma Forum Guideline. Br J Haematol. 2021;193(2):245–268. doi: 10.1111/bjh.17410
   PubMed Web of Science ®Google Scholar
• Lonial S, Bowser AD, Chari A, et al. Expert consensus on the incorporation of anti-CD38 monoclonal antibody therapy into the management of newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23(11):815–824. doi: 10.1016/j.clml.2023.07.001
   PubMed Web of Science ®Google Scholar
• Giri S, Grimshaw A, Bal S, et al. Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors. JAMA Onc. 2020;6(11):1–8. doi: 10.1001/jamaoncol.2020.4338
   Web of Science ®Google Scholar
• Premkumar V, Pan S, Lentzsch S, et al. Use of daratumumab in high risk multiple myeloma: A meta-analysis. eJHaem. 2020;1:267–271. doi: 10.1002/jha2.47
   PubMedGoogle Scholar
• Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29–38. doi: 10.1016/S0140-6736(19)31240-1
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–2115. doi: 10.1056/NEJMoa1817249
   PubMed Web of Science ®Google Scholar
• Kumar SK, Moreau P, Bahlis NJ, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 maia study. Blood. 2022;140(Supplement 1):10150–10153. doi: 10.1182/blood-2022-163335
   Google Scholar
• Mateos M-V, Dimopoulos MA, Cavo M, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2018;378(6):518–528. doi: 10.1056/NEJMoa1714678
   PubMed Web of Science ®Google Scholar
• Mateos M-V, San-Miguel J, Cavo M, et al. Daratumumab plus bortezomib, Melphalan, and prednisone (D-VMP) versus bortezomib, Melphalan, and prednisone (VMP) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 Alcyone study. Blood. 2022;140(Supplement 1):10157–10159. doi: 10.1182/blood-2022-163347
   Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(8):754–766. doi: 10.1056/NEJMoa1606038
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Chanan-Khan A, Weisel K, et al. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. J Clin Oncol. 2022;41(8):1600–1609. doi: 10.1200/JCO.21.02734
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331. doi: 10.1056/NEJMoa1607751
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial. J Clin Oncol. 2023;41(8):1590–1599. doi: 10.1200/JCO.22.00940
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Quach H, Mateos M-V, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186–197. doi: 10.1016/S0140-6736(20)30734-0
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Quach H, Mateos M-V, et al. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. Blood Adv. 2023;7(14):3739–3748. doi: 10.1182/bloodadvances.2023010026
   PubMed Web of Science ®Google Scholar
• Moreau P, Facon T, Usmani S, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (rd) in Transplant-Ineligible Patients (pts) with newly diagnosed multiple myeloma (NDMM): clinical assessment of key subgroups of the phase 3 maia study. Blood. 2022;140(Supplement 1):7297–7300. doi: 10.1182/blood-2022-163494
   Google Scholar
• Moreau P, Facon T, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): clinical assessment of key subgroups of the phase 3 MAIA study. In: Poster presented at: 64th American Society of Hematology (ASH) Annual Meeting and Exposition; December 10–13, 2022; New Orleans, LA/Virtual meeting.
   Google Scholar
• Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(6):801–812. doi: 10.1016/S1470-2045(21)00128-5
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301–313. doi: 10.1056/NEJMoa2312054
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936–945. doi: 10.1182/blood.2020005288
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Sborov DW, Laubach J, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10(10):e825–e837. doi: 10.1016/S2352-3026(23)00217-X
   PubMed Web of Science ®Google Scholar
• Chari A, Kaufman JL, Laubach JP, et al. Daratumumab plus lenalidomide, Bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (pts): final analysis of Griffin among clinically relevant subgroups. Blood. 2022;140(Supplement 1):7278–7281. doi: 10.1182/blood-2022-162339
   Google Scholar
• Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2021;40(25):2901–2912. doi: 10.1200/JCO.21.01935
   PubMed Web of Science ®Google Scholar
• Costa LJ, Chhabra S, Medvedova E, et al. Outcomes of MRD-Adapted treatment modulation in patients with newly diagnosed multiple myeloma receiving daratumumab, Carfilzomib, lenalidomide and dexamethasone (dara-KRd) and autologous transplantation: extended follow up of the master trial. Blood. 2022;140(Supplement 1):7275–7277. doi: 10.1182/blood-2022-156730
   Google Scholar
• Touzeau C, Perrot A, Hulin C, et al. Daratumumab carfilzomib lenalidomide and dexamethasone with tandem transplant in high-risk newly diagnosed myeloma. Blood. 2024;143(20):2029–2036. doi: 10.1182/blood.2023023597
   PubMedGoogle Scholar
• Landgren O, Hultcrantz M, Diamond B, et al. Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: The MANHATTAN nonrandomized clinical trial. JAMA Onc. 2021;7(6):862–868. doi: 10.1001/jamaoncol.2021.0611
   PubMed Web of Science ®Google Scholar
• Kaiser MF, Hall A, Walker K, et al. Daratumumab, Cyclophosphamide, Bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in Ultra-High-Risk multiple myeloma. J Clin Oncol. 2023;41(23):3945–3955. doi: 10.1200/JCO.22.02567
   PubMed Web of Science ®Google Scholar
• Mohan M, Weinhold N, Schinke C, et al. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. Br J Haematol. 2020;189(1):67–71. doi: 10.1111/bjh.16292
   PubMed Web of Science ®Google Scholar
• Barbieri E, Maccaferri M, Leonardi G, et al. Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience. Ann Hematol. 2022;101(12):2777–2779. doi: 10.1007/s00277-022-04978-6
   PubMed Web of Science ®Google Scholar
• Stork M, Spicka I, Radocha J, et al. Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis. Ann Hematol. 2023;102(6):1501–1511. doi: 10.1007/s00277-023-05188-4
   PubMed Web of Science ®Google Scholar
• Kimmich CR, Terzer T, Benner A, et al. Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: high efficacy, relevant toxicity and main adverse effect of gain 1q21. Am J Hematol. 2021;96(7):e253–e257. doi: 10.1002/ajh.26191
   PubMed Web of Science ®Google Scholar
• Lim KJC, Wellard C, Moore E, et al. Impact of 1q21 gain and amplification on daratumumab-treated multiple myeloma patients: real-world data from the Australia-New Zealand and Asia-Pacific Myeloma and related diseases registries. Blood. 2023;142(Supplement 1):3325–3325. doi: 10.1182/blood-2023-173896
   Google Scholar
• Hu X, Wu C-H, Cowan JM, et al. Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy. Ann Hematol. 2022;101(2):369–378. doi: 10.1007/s00277-021-04704-8
   PubMed Web of Science ®Google Scholar
• Szabo AG, Klausen TW, Levring MB, et al. The real-world outcomes of multiple myeloma patients treated with daratumumab. PLoS One. 2021;16(10):e0258487. doi: 10.1371/journal.pone.0258487
   PubMed Web of Science ®Google Scholar
• Højholt KL, Gregersen H, Szabo AG, et al. Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients. Hematol Oncol. 2021;39(4):521–528. doi: 10.1002/hon.2906
   PubMed Web of Science ®Google Scholar
• Parrondo RD, Gardner LB, Alhaj Moustafa M, et al. Therapeutic outcomes of relapsed-refractory multiple myeloma patients with + 1q treated with daratumumab-based regimens: a retrospective analysis. Blood. 2022;140(Supplement 1):7237–7238. doi: 10.1182/blood-2022-169533
   Google Scholar
• Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096–2107. doi: 10.1016/S0140-6736(19)32556-5
   PubMed Web of Science ®Google Scholar
• Richardson PG, Perrot A, San-Miguel J, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022;23(3):416–427. doi: 10.1016/S1470-2045(22)00019-5
   PubMed Web of Science ®Google Scholar
• Moreau P, Dimopoulos M-A, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361–2371. doi: 10.1016/S0140-6736(21)00592-4
   PubMed Web of Science ®Google Scholar
• Martin T, Dimopoulos M-A, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023;13(1):72. doi: 10.1038/s41408-023-00797-8
   PubMed Web of Science ®Google Scholar
• Harrison SJ, Perrot A, Alegre A, et al. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol. 2021;194(1):120–131. doi: 10.1111/bjh.17499
   PubMed Web of Science ®Google Scholar
• Martin T, Richardson PG, Facon T, et al. Primary outcomes by + 1q status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA. Haematologica. 2022;107(10):2485–2491. doi: 10.3324/haematol.2022.280660
   PubMed Web of Science ®Google Scholar
• Spicka I, Moreau P, Martin TG, et al. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. J Clin Oncol. 2021;39(15_suppl):8042–8042. doi: 10.1200/JCO.2021.39.15_suppl.8042
   Web of Science ®Google Scholar
• Moreau P, Spicka I, Suzuki K, et al. Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+ status: Updated results from the phase 3 IKEMA study. J Clin Oncol. 2023;41(16_suppl):8029–8029. doi: 10.1200/JCO.2023.41.16_suppl.8029
   Web of Science ®Google Scholar
• Goldschmidt H, Mai EK, Bertsch U, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9(11):e810–e821. doi: 10.1016/S2352-3026(22)00263-0
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Mai EK, Nievergall E, et al. Addition of Isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: the phase III GMMG-HD7 trial. Blood. 2021;138:463–463. doi: 10.1182/blood-2021-145097
   Google Scholar
• Mai EK, Bertsch U, Fenk R, et al. Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed multiple myeloma patients with high-risk cytogenetics: a subgroup analysis from the GMMG-HD7 trial. Hemasphere. [2022 Jun 23];6(Suppl):820–821. doi: 10.1097/01.HS9.0000846588.94000.04
   Google Scholar
• Leypoldt LB, Besemer B, Asemissen AM, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia. 2022;36(3):885–888. doi: 10.1038/s41375-021-01431-x
   PubMed Web of Science ®Google Scholar
• Leypoldt LB, Tichy D, Besemer B, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol. 2023;42(1):26–37. doi: 10.1200/JCO.23.01696
   PubMed Web of Science ®Google Scholar
• O’Donnell EK, Mo CC, Yee AJ, et al. A Phase II Study of isatuximab, once weekly carfilzomib, lenalidomide, dexamethasone, in newly diagnosed, transplant-eligible multiple myeloma (the SKylaRk trial). Blood. 2023;142(Supplement 1):4671–4671. doi: 10.1182/blood-2023-181019
   Google Scholar
• Gay F, Roeloffzen W, Dimopoulos MA. Results of the Phase III randomized iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone Vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Blood. 2023;142(Supplement 1):4–4. doi: 10.1182/blood-2023-177546
   PubMedGoogle Scholar
• Orlowski RZ, Goldschmidt H, Cavo M, et al. Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM). J Clin Oncol. 2018;36(15_suppl):TPS8055–TPS8055. doi: 10.1200/JCO.2018.36.15_suppl.TPS8055
   Web of Science ®Google Scholar
• Leleu X, Martin T, Weisel K, et al. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes. Ann Hematol. 2022;101(10):2123–2137. doi: 10.1007/s00277-022-04917-5
   PubMed Web of Science ®Google Scholar
• Ye L, Zhou F, Cheng D, et al. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials. Front Oncol. 2023;13:1240318. doi: 10.3389/fonc.2023.1240318
   PubMed Web of Science ®Google Scholar
• van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131:13–29. doi: 10.1182/blood-2017-06-740944
   PubMed Web of Science ®Google Scholar
• Zhu C, Song Z, Wang A, et al. Isatuximab acts through fc-dependent, independent, and direct pathways to kill multiple myeloma cells. Front Immunol. 2020;11:1771. doi: 10.3389/fimmu.2020.01771
   PubMed Web of Science ®Google Scholar
• Schmidt TM, Boise LH. Agent myeloma has a new weapon from (ch1)Q. Blood. 2022;139(13):1927–1928. doi: 10.1182/blood.2021015336
   PubMed Web of Science ®Google Scholar
• Xu J, Wang Y, Li P, et al. PRUNE1 (located on chromosome 1q21.3) promotes multiple myeloma with 1q21 gain by enhancing the links between purine and mitochondrion. Br J Haematol. 2023;203(4):599–613. doi: 10.1111/bjh.19088
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Casneuf T, van Velzen J, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7):959–970. doi: 10.1182/blood-2016-03-703439
   PubMed Web of Science ®Google Scholar
• Ogiya D, Liu J, Ohguchi H, et al. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood. 2020;136(20):2334–2345. doi: 10.1182/blood.2019004332
   PubMed Web of Science ®Google Scholar
• Teoh PJ, Chung T-H, Chng PYZ, et al. IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification. Haematologica. 2020;105(5):1391–1404. doi: 10.3324/haematol.2019.221176
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631. doi: 10.1056/NEJMoa1505654
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10(9):1–10. doi: 10.1038/s41408-020-00357-4
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379(19):1811–1822. doi: 10.1056/NEJMoa1805762
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2021;8(1):e45–e54. doi: 10.1016/S2352-3026(20)30354-9
   PubMed Web of Science ®Google Scholar
• Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(10):1317–1330. doi: 10.1016/S1470-2045(20)30452-6
   PubMed Web of Science ®Google Scholar
• Kapoor P, Schmidt T, Jacobus S, et al. OAB-052: Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial. Clin Lymphoma Myeloma Leuk. 2021;21:S33–S34. doi: 10.1016/S2152-2650(21)02126-1
   Web of Science ®Google Scholar
• Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22(12):1705–1720. doi: 10.1016/S1470-2045(21)00535-0
   PubMed Web of Science ®Google Scholar
• D’Agostino M, Ruggeri M, Aquino S, et al. Impact of gain and amplification of 1q in newly diagnosed multiple myeloma patients receiving carfilzomib-based treatment in the forte trial. Blood. 2020;136(Supplement 1):38–40. doi: 10.1182/blood-2020-137060
   Google Scholar
• D’Agostino M, Belotti A, Zamagni E, et al. OAB-055: Gain and amplification of 1q induce transcriptome deregulation and worsen the outcome of newly diagnosed multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2021;21:S34. doi: 10.1016/S2152-2650(21)02127-3
   Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–1634. doi: 10.1056/NEJMoa1516282
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Bahlis NJ, Chng W-J, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017;130(24):2610–2618. doi: 10.1182/blood-2017-06-791228
   PubMed Web of Science ®Google Scholar
• Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563–1573. doi: 10.1016/S0140-6736(20)32292-3
   PubMed Web of Science ®Google Scholar
• Richard S, Chari A, Delimpasi S, et al. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by cytogenetic risk. Am J Hematol. 2021;96(9):1120–1130. doi: 10.1002/ajh.26261
   PubMed Web of Science ®Google Scholar
• Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. [2022 Aug 11];387(6):495–505. doi: 10.1056/NEJMoa2203478
   PubMed Web of Science ®Google Scholar
• Bahlis NJ, Costello CL, Raje NS, et al. Elranatamab in relapsed or refractory multiple myeloma: the magnetisMM-1 phase 1 trial. Nat Med. 2023 Oct;29(10):2570–2576. doi: 10.1038/s41591-023-02589-w
   PubMed Web of Science ®Google Scholar
• Martino EA, Bruzzese A, Iaccino E, et al. Belantamab mafodotin in multiple myeloma. Expert Opin Biol Ther. 2023 Jul;23(11):1043–1047. doi: 10.1080/14712598.2023.2218543
   PubMed Web of Science ®Google Scholar
• Rodriguez -Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002–1014. doi: 10.1056/NEJMoa2213614
   PubMed Web of Science ®Google Scholar
• San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335–347. doi: 10.1056/NEJMoa2303379
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716. doi: 10.1056/NEJMoa2024850
   PubMed Web of Science ®Google Scholar
• Lonial S, Popat R, Hulin C, et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol. 2022;9(11):e822–e832. doi: 10.1016/S2352-3026(22)00290-3
   PubMed Web of Science ®Google Scholar
• Richardson PG, Trudel S, Popat R, et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med. 2023;389(11):1009–1022. doi: 10.1056/NEJMoa2303194
   PubMed Web of Science ®Google Scholar